



Geneoscopy receives Z-Code from Palmetto GBA for its Noninvasive Multi-Target Stool RNA Colorectal Cancer Screening Test

ST. LOUIS, April 12, 2023 / Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced the assignment of a unique DEX Z-code from Palmetto GBA's MolDX program for the company's noninvasive multi-target stool RNA (mt-sRNA) colorectal cancer screening test.

"Obtaining this Z-code is vital for market access and aligns with our plans for commercial launch," said Andrew Barnell, Chief Executive Officer of Geneoscopy. "Once approved and launched, we anticipate Geneoscopy's noninvasive mt-sRNA colorectal cancer screening test will offer patients and healthcare providers a convenient and reliable CRC screening option for earlier detection and treatment."

The assignment of the DEX Z-code as a test identifier is a significant step as Geneoscopy awaits the US Food and Drug Administration's decision regarding the PMA submitted in January 2023. Geneoscopy's test is not FDA approved and not available for sale.

About Geneoscopy Inc.

Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and healthcare providers with the confidence to detect, prevent and monitor disease with our innovative tests developed to transform gastrointestinal health. Beyond colorectal cancer screening, Geneoscopy is developing tests for diagnosis, treatment selection, and therapy monitoring in other disease areas in partnership with leading universities and biopharmaceutical companies. For more information, visit www.geneoscopy.com and follow the company on [LinkedIn](#).

Geneoscopy Inc. Forward-Looking Statements

This release includes information about Geneoscopy's future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, which constitute forward-looking statements. These forward-looking statements are based on the Company's



reasonable estimates of future results or trends. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside the Company's control. Geneoscopy's actual results and financial condition may differ materially from those in the forward-looking statements. Although the Company believes its business plans and objectives reflected in or suggested by these forward-looking statements are reasonable, such plans or objectives may not be achieved. The actual results may differ substantially from the projected result.

MEDIA CONTACT

Judy Pretto

Director, Marketing Communications

815.534.0521

media@geneoscopy.com